V. Klein

[Dose constraints to organs at risk for conformational and stereotactic radiotherapy: Small bowel and duodenum].

P. Maingon, J. Castelli, E. Chajon, 2017, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

EGFR Expression Is Unreliable to Decide for Cetuximab Treatment in Patients with Metastatic Colorectal Cancer: Results from “ERBITUX-OUEST”

J. Douillard, N. Padilla, J. Raoul, 2016 .

Efficacy and safety of panitumumab in a cohort of patients with metastatic colorectal cancer in France: PANI OUEST, a post-EMA-approval descriptive study with a geriatric oncology focus.

J. Douillard, J. Metges, Z. Alavi, 2020, The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology.

Radiotherapy with high dose rate brachytherapy boost and concomitant chemotherapy for Stages IIB and III esophageal carcinoma: results of a pilot study.

G. Calais, L. de Calan, P. Bourlier, 1997, International journal of radiation oncology, biology, physics.

Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.

L. Collette, G. Calais, M. Bolla, 2014, The Lancet. Oncology.

Evaluation in usual practice of the bevacizumab-FOLFIRI combination for the first-line treatment of patients with unresectable metastatic colorectal cancer treated in 2006: focus on resected patients and oncogeriatrics

J. Douillard, P. Langlet, E. Jobard, 2014, Oncologie.